Skip to content

Study · Not a test of the peptide alone · 2025

11 results

Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review.

Yu H, Davoudi M, Sadegh-Nejadi S, Miao X, Bagherieh M, Afrisham R

Journal of translational medicine25 Apr 2025Cited by 13 (Europe PMC)

PMID40281607 (opens in a new tab)PMCIDPMC12032824 (opens in a new tab)DOI10.1186/s12967-025-06461-y (opens in a new tab)PepBankPUB-40281607
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewMechanism

    In reviewed T2D human studies, pooled GLP-1RA/metformin regimens modulated non-exosomal miR-27b; its signed change, exact contrast and native-liraglutide estimate were unstated.

    In plain wordsIn reviewed people with T2D, pooled GLP-1/metformin regimens changed miR-27b; direction and comparison were unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedNon-exosomal miR-27b modulation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Human studies showed GLP-1RA combined with metformin modulated non-exosomal miR-27b, miR-130a, and miR-210a, which were linked to cardiovascular health.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewMechanism

    In reviewed T2D human studies, pooled GLP-1RA/metformin regimens modulated non-exosomal miR-130a; its signed change, exact contrast and native-liraglutide estimate were unstated.

    In plain wordsIn reviewed people with T2D, pooled GLP-1/metformin regimens changed miR-130a; direction and comparison were unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedNon-exosomal miR-130a modulation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Human studies showed GLP-1RA combined with metformin modulated non-exosomal miR-27b, miR-130a, and miR-210a, which were linked to cardiovascular health.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewMechanism

    In reviewed T2D human studies, pooled GLP-1RA/metformin regimens modulated non-exosomal miR-210a; its signed change, exact contrast and native-liraglutide estimate were unstated.

    In plain wordsIn reviewed people with T2D, pooled GLP-1/metformin regimens changed miR-210a; direction and comparison were unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedNon-exosomal miR-210a modulation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Human studies showed GLP-1RA combined with metformin modulated non-exosomal miR-27b, miR-130a, and miR-210a, which were linked to cardiovascular health.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewMechanism

    In reviewed T2D patients on metformin, higher baseline miR-378-3p correlated with greater HbA1c improvement after one year of pooled GLP-1RA therapy; no liraglutide-specific coefficient or baseline-marker reference was reported.

    In plain wordsIn reviewed T2D patients on metformin, higher baseline miR-378-3p was linked to greater HbA1c improvement after one year of GLP-1 therapy.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c improvement association with baseline miR-378-3p
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In T2DM patients on metformin, higher baseline miR-378-3p or miR-126-3p correlated with greater HbA1c improvement after one year of GLP-1RA therapy.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewMechanism

    In reviewed T2D patients on metformin, higher baseline miR-126-3p correlated with greater HbA1c improvement after one year of pooled GLP-1RA therapy; no liraglutide-specific coefficient or baseline-marker reference was reported.

    In plain wordsIn reviewed T2D patients on metformin, higher baseline miR-126-3p was linked to greater HbA1c improvement after one year of GLP-1 therapy.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c improvement association with baseline miR-126-3p
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In T2DM patients on metformin, higher baseline miR-378-3p or miR-126-3p correlated with greater HbA1c improvement after one year of GLP-1RA therapy.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneSystematic reviewMechanism

    In reviewed T2D patients, more than 5% weight loss correlated with higher baseline miR-15a-5p in pooled GLP-1RA evidence; no native-liraglutide coefficient or exact marker reference was reported.

    In plain wordsIn reviewed T2D patients, more than 5% weight loss was linked to higher baseline miR-15a-5p in pooled GLP-1 evidence.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight loss association with baseline miR-15a-5p
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Notably, > 5% weight loss correlated with higher baseline levels of miR-15a-5p.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneSystematic reviewOther

    In the searched GLP-1RA/T2D miRNA synthesis, no clinical studies reported exosomal miRNAs; this is a coverage absence, not a human biological null or liraglutide-specific negative result.

    In plain wordsIn the T2D GLP-1 review, no clinical studies reported exosomal microRNAs; this does not establish a biological null.

    Peptide
    Liraglutide
    Outcome
    Not applicableAbsence of clinical exosomal-miRNA evidence
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Pharmacology

    Source sentences

    Summary
    No clinical studies reported exosomal miRNAs,
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08AnimalNot a test of Liraglutide aloneOther designMechanism

    In unsplit preclinical T2D evidence, pooled GLP-1RA monotherapy increased cardiovascular action through miR-29b-3p/miR-34a-5p/miR-26a-5p/miR-181a-5p/miR-93-5p; species, model, comparator and native-drug effect were unstated.

    In plain wordsIn preclinical T2D models, pooled GLP-1 therapy increased cardiovascular action through several microRNAs; species and comparison were unspecified.

    Peptide
    Liraglutide
    Outcome
    IncreaseCardiovascular action via non-exosomal microRNAs
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Preclinical findings suggested GLP-1RA monotherapy increased cardiovascular action via non-exosomal miR-29b-3p, miR-34a-5p, miR-26a-5p, miR-181a-5p, and miR-93-5p.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  9. 09AnimalNot a test of Liraglutide aloneOther designMechanism

    In unsplit preclinical T2D evidence, silencing miR-204, miR-375 or miR-139-5p augmented exendin-4/liraglutide monotherapy-induced glucose-stimulated insulin secretion; the source does not isolate a native-liraglutide drug effect.

    In plain wordsIn preclinical T2D models, microRNA silencing increased insulin secretion with exendin-4/liraglutide; the comparison and species were unspecified.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlucose-stimulated insulin secretion after microRNA silencing
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Silencing non-exosomal miR-204, miR-375, or miR-139-5p augmented exendin-4/liraglutide monotherapy-induced glucose-stimulated insulin secretion.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 10AnimalNot a test of Liraglutide aloneOther designMechanism

    In unsplit preclinical T2D/NAFLD models, pooled GLP-1RA monotherapy reduced hepatic lipid accumulation via miR-5120-related ABHD6 modulation; species, comparator and native-drug coefficient were unstated.

    In plain wordsIn preclinical T2D/fatty-liver models, pooled GLP-1 therapy reduced liver lipids; species and comparison were unspecified.

    Peptide
    Liraglutide
    Outcome
    DecreaseHepatic lipid accumulation
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Interestingly, GLP-1RA monotherapy reduced hepatic lipid accumulation in T2DM models with comorbid NAFLD via ABHD6 mRNA modulation by non-exosomal miR-5120.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  11. 11AnimalNot a test of Liraglutide aloneOther designMechanism

    In an unsplit preclinical estrogen-deficient T2D study, GLP-1RA-induced exosomal let-7c-2-3p/miR-322-3p was linked to bone protection; signed outcome, species, comparator and native-drug coefficient were unstated.

    In plain wordsIn preclinical estrogen-deficient T2D models, GLP-1-related exosomal microRNAs were linked to bone protection; signed change, species and comparison were unspecified.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBone protection association with exosomal microRNAs
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    No clinical studies reported exosomal miRNAs, but a preclinical study linked GLP-1RA-induced exosomal let-7c-2-3p/miR-322-3p to bone protection in estrogen-deficient T2DM models.
    2 context sentences
    Summary · context
    This review synthesizes current evidence of GLP-1RA-induced exosomal and non-exosomal miRNA changes in human and animal models of T2DM.
    Summary · context
    Scopus, PubMed/Medline, Web of Science, and Google Scholar searches returned 83 studies, of which 11 met the study eligibility criteria (PROSPERO No: CRD42024586000).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.